Skip to Content

About Us

Diagnostic Assays

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.


MDA10-116
Specific Copy Number Aberrations as Predictors of Breast Cancer Recurrence and Treatment Response
Please contact the office for more information on this technology.


MDA10-084
The BATTLE Trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)
Please contact the office for more information on this technology.


MDA10-063
Classifiers Predicting Recurrence Risk of Tamoxifen-treated ER+Breast Cancers
Please contact the office for more information on this technology.


MDA10-019
A Plasma Based Biomarker Assay for Pancreatic Cancer
Please contact the office for more information on this technology.


MDA10-014
A Test for the Stratification of Triple Receptor-Negative Breast Cancer Patients Based on Prognosis
Please contact the office for more information on this technology.


MDA10-012
A Novel Molecular Method to Improve the Diagnosis of Cancer
Please contact the office for more information on this technology.


MDA09-075
Quantitative RT-PCR Detection for Genes in Peripheral Blood of Breast Cancer Patients
Please contact the office for more information on this technology.


MDA09-074
A Nine Gene Predictor of Therapy Response in Adult Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Please contact the office for more information on this technology.


MDA09-041
Genetic Marker(s) associated with Cannabinoid Receptor Type 2 (CB2) Modulators
Please contact the office for more information on this technology.


MDA09-026
Marker-based Prognostic Risk Score for Esophagealgastric Cancer
Please contact the office for more information on this technology.


MDA09-018
Single Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility
Please contact the office for more information on this technology.


MDA09-005
A MicroRNA Signature to Predict Prognosis in Human Heart Failure
Please contact the office for more information on this technology.


MDA08-153
An Improved Classification Scheme for Breast Cancer Based on Disease Dynamics
Please contact the office for more information on this technology.


MDA08-074
Diagnostic Testing for the Presence of Cancer by Detecting p-STAT-3 in Perpherial Blood
WO/2010/081158


MDA07-064
MicroRNA 1960a and micro RNA 196b (miR-196a and miR-196b) are Candidate microRNA Regulators of Annexin A1(ANXA1) Esophageal and Breast Cancers
WO2010/048317


MDA07-028
Identification of Ovarian Neoplasms by Measuring Metabolites in Serum
Please contact the office for more information on this technology.


MDA06-122
An Assay to Predict Recurrence Risk in Breast Cancer using the Novel Tumor Suppressor DEAR1
Please contact the office for more information on this technology.


MDA06-105
Methods for Assessing Cancer Susceptibility to Carcinogens in Tobacco Products
WO2007/146883


MDA06-103
Developing a highly sensitive assay for Circulating Tumor cells using patented biomarkers
WO2010/005991


MDA06-088
Prediction of Therapeutic Response for Anti-tyrosine Kinases using Theranostc Antiphosphotyrosine Antibody: Composition, Manufacturing and Use
WO2008/064040
US-2010-0104511


MDA06-024
Gene Expression Profiling of Localized Esophageal Carcinomas: Association with Pathologic Response to Preoperative Chemoradiation
WO2008/073878
US-2010-0216131


MDA04-108
Telomere Length as Measured on Cytological Specimens Predicts Presence of Cancer
US-2009-0162839-A1
WO2006/026714


MDA03-097
Taxan Chemosensitivity Prediction Test
US-2005-0131057-A1
WO2005/020794


MDA02-038
Fusion Proteins and Mutants for Detecting Gene Expression in vitro and in vivo
7,176,187
WO02/064747
US-2007-0161045-A1


MDA01-053
Identification of Tumor Markers and Potential Diagnostic and Therapeutic Targets for Human Gliomas By Gene Expression Profiling
7,341,552
WO03/078603


MDA00-038
Cancer Prognostic and Diagnostic Assays
6,797,471
7,741,034
WO02/12563A2
US-2010-0240060-A1


MDA00-001
Haploid Protein Expression Test for Detection of Mutations
6,818,401
WO02/29107


MDA98-011
Rapid Analysis of Gene Expression (RAGE)
6,221,600
7,294,487
WO01/27329


MDA97-041
Synthetic Peptides from Human Papillomavirus (HPV) as Markers of Protective Immunity and as Reagents for Immunotherapy and Prophylaxis of HPV-Associated Cervical Cancer
7,410,758
WO2003/008649
7,659,071


MDA89-015
Marker Protein and Antibodies Thereto for Cancer Risk Assessment & Diagnosis
5,310,653
5,411,868
5,773,215

For More Information


© 2014 The University of Texas MD Anderson Cancer Center